Salvagno L, Ferrazzi E, Sileni V C, Maggi S, Tredese F, Bedendo C, Russo M P, Fiorentino M V, Ceriotti G
Tumori. 1985 Apr 30;71(2):127-33. doi: 10.1177/030089168507100207.
Serum lipid-bound sialic acid (LSA) was measured with a recently described procedure in 108 healthy subjects and in 138 patients with a variety of solid tumors and hematologic malignancies. At the time of serum sampling, 128 patients had active disease and 10 patients had no evidence of disease. LSA was elevated in 104 of 128 (81.2%) patients with active disease, while carcinoembryonic antigen, analyzed in 74, was elevated only in 21 (28.4%) (P less than 0.05). Sensitivity of the serum LSA test ranged from 66% for breast and gastrointestinal cancer to 92% for lung cancer. In patients with lung cancer, ovarian cancer or Hodgkin's disease, LSA was correlated with the extent of disease and it also proved to be useful in following the course of disease. Our preliminary data indicate that this test can be used as a monitor of tumor burden.
采用最近描述的方法，对108名健康受试者以及138名患有各种实体瘤和血液系统恶性肿瘤的患者进行了血清脂质结合唾液酸（LSA）检测。在采集血清时，128例患者患有活动性疾病，10例患者无疾病证据。128例活动性疾病患者中有104例（81.2%）LSA升高，而74例接受癌胚抗原检测的患者中仅有21例（28.4%）升高（P<0.05）。血清LSA检测的敏感性在乳腺癌和胃肠道癌中为66%，在肺癌中为92%。在肺癌、卵巢癌或霍奇金病患者中，LSA与疾病程度相关，并且在疾病进程监测中也被证明是有用的。我们的初步数据表明，该检测可作为肿瘤负荷的监测指标。
